https://www.facebook.com/Sen-Sore-LLC-141871439251267/

ASSESSx

ASSESSx Technology Ltd. is a medical device company that is developing a patented bio-sensor that will locate, monitor and help treat inflammatory pain. Doctors involved in treating pain have long been stifled by the subjectivity of it, relying on the patient to rate their own pain, with no objective way to validate it or measure how intense it really is. With current methods and devices lacking the definitive diagnostics to qualify or quantify pain and inflammation, health care providers are left severely hampered in the accurate assessment of a patient’s pain level, which is critical to ensure the effectiveness of treatments. The Advanced Bio-sensor for Assessment, Treatment & Evaluation, Quad-recorder (ABATE Qr) provides doctors, nurses and medical practitioners a tool to objectively locate and measure pain-inducing inflammation. As a supplement to clinical palpation, and with the ability to accurately measure soft tissue inflammation, it will transform the way we diagnose and treat pain and disease. The bio-sensors measure and compare differences between painful soft tissues and pain-free soft tissues, providing practitioners with the information needed to objectively pinpoint the underlying cause of pain through findings of soft tissue inflammation. The ABATE Qr has the ability to treat chronic pain without the use of drugs using compression massage techniques, alleviating the suffering of millions of people every year. It also allows for the continuous monitoring of a patient, obtaining sufficient data to objectify pain. TECHNOLOGY The ABATE Qr merges four FDA-approved bio-sensors into a one single probe that simultaneously images multiple facets of inflammatory pain. These FDA approved technologies are independently expensive to purchase, time-consuming to operate, and only look a single facet of inflammation. Combined they display a much more accurate and objective image. The combined bio-sensors measure: Each year, chronic pain affects over 100 million Americans and costs the US economy upwards of $635 billion, making it not just a problem, but an epidemic. With pain now being consider the “fifth vital sign”, the world market for pain management drugs and devices reaching $35 billion, and the expectation for further growth spurred as a result of the aging population, there has been increased awareness for pain and the need for effective treatments. ASSESSx will capitalize on this trend, targeting hospitals, medical facilities, and research and training institutions, and is well positioned to become an effective and demanded pain diagnostics device. View all posts by ASSESSx